Clinical Trial: A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants

U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07590466) titled 'A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian Participants' on April 29.

Brief Summary: The goal of this Phase 1 clinical trial is to compare the pharmacokinetics and safety of a fixed-dose combination tablet (ATB-U101) versus co-administration of its individual components in healthy Caucasian adult volunteers. The main questions it aims to answer are:

* Is the Cmax of Olmesartan and Dapagliflozin bioequivalent across the three treatment regimens?

* Is the AUClast of Olmesartan and Dapagliflozin bioequivalent across the three treatment regimens?...